Plain-English translation of NCT07312422 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether combining three types of treatment — low-dose radiation therapy, a new immunotherapy drug called , and standard chemotherapy — works better together than chemotherapy alone for advanced pancreatic cancer. The idea is that radiation may "wake up" the immune system to recognize and attack cancer cells, while the medication helps your immune system fight the cancer more effectively.
Pancreatic cancer is very hard to treat, and immunotherapy drugs alone haven't worked well for most patients with this disease. Researchers believe that combining this medication with radiation and chemotherapy might make the treatment more powerful by helping your body's immune system recognize and destroy cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic regularly over several months. On Day 1 of each treatment cycle (roughly every 3 weeks), you would receive a low-dose radiation treatment to one tumor. The next day, you would receive an infusion of combined with chemotherapy. This cycle repeats every 3 weeks until your cancer stops responding to treatment, you experience side effects you cannot tolerate, or for up to 2 years — whichever comes first.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China